+ Sign up for our e-mail newsletter!

CitraPure® The Only Acetate Free Citric Acid Concentrate

Recent studies have demonstrated the clinical advantages of using an acetate-free dialysate that contains citrate; acetate promotes inflammation, and replacement of acetate by citrate reduces inflammation.* Citrate chelates calcium ions and inhibits coagulation, providing anticoagulation benefits.

Patients Just Feel Better
“Since dialyzing with CitraPure® Citric Acid I’ve never felt so good! I’ve been on dialysis 6 1/2 years and after every treatment I felt worn out and washed-out. It took me until the next morning to feel normal again. Then my clinic started using CitraPure® and after my very first dialysis treatment, I immediately felt better. I had my energy back. Now, I feel so good that my wife and I occasionally go out to dinner right after my treatment. CitraPure® has made a very positive impact in my life.”

Tom Barratta, Hemodialysis Patient, USA

  • CitraPure
  • Study
  • MSDS
  • Products

Clinical Advantage of Acetate Free Dialysate Containing Citrate

Clinical Advantage of Acetate Free Dialysate Containing Citrate
(Download The study here)
Department of Internal Medicine, Division of Kidney and Dialysis
Hyogo College of Medicine, Nishinomiya, Japan
Takahiro Kuragano and Takeshi Nakanishi

Summary of Results:
• Metabolic acidosis: In the patients with low HCO3 - levels(<20mEq/L) , HCO3 was significantly increased in the AFCD period compared with first AD period.
• Anemia: In the patients with target Hb (≥10g/dL), the dose of ESA decreased in the AFCD period, while Hb levels were maintained during each dialysate period. In the patients with lower Hb (<10g/dL) levels, Hb levels increased significantly in the AFCD period without increasing ESA and iron dose.
• Nutritional condition: In the patients with lower albumin levels, serum albumin significantly increased in the AFCD period compared with the AD period.
• PTH level: In the patients with normal intact-PTH levels (≥60pg/mL), intact- PTH and BAP levels did not differ among the 3 periods. In the patients with hypo-parathyroidism (intact-PTH <60pg/mL), intact-PTH and BAP levels were significantly increased in the AFCD period.
• These improvements of metabolic acidosis, anemia, malnutrition, and low turnover bone disease in AFCD period were totally dissipated in the second AD period.

Conclusion:
1. HD treatment with AFCD may improve the condition of patients with metabolic acidosis, hyporesponsiveness to ESA, malnutritional condition, or low turnover bone disease.
2. The most interesting finding in this study was that AFCD did not overcorrect HCO3 - and intact-PTH.

CitraPure - Material Safety Data Sheets (MSDS): Download here

CitraPure® Formulations:
Please contact Dial Medical Customer Service for pricing and other available formulations, 800-346-2080, info@dialmedsupply.com.


CitraPure® is packaged - 4 each 3.78 Liter (1 Gallon) containers per case (42 lbs.)
Formula Dilution Na Ca K Mg Chloride Dex Acetate Citrate
L3-145-4 36.83X 81.0 2.5 2.0 1.0 86.5 100 0.0 2.4
L4-102-4 45X 100.0 0.0 0.0 1.0 101.0 100 0.0 2.4
L4-116-4 45X 100.0 2.5 2.0 1.0 105.5 100 0.0 2.4
L4-216.4 45X 100.0 2.5 2.0 1.0 105.5 200 0.0 2.4